No effect of low-dose statins treatment on cerebral blood flow in humans with atherosclerotic cerebrovascular disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 27, Issue 9, 2007, Pages 1643-1648

  Derdeyn, Colin P ^a,b   Carpenter, David A ^b   Videen, Tom O ^b   Grubb Jr , Robert L ^b   Powers, William J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; CBF measurements; Cerebral hemodynamics; Cerebrovascular disease

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BASAL GANGLION; BRAIN BLOOD FLOW; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMISPHERE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; BRAIN; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 34548139367     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600469     Document Type: Article

References (30)

1. Amarenco P, Tonkin AM (2004) Statins for stroke prevention: disappointment and hope. Circulation 109:III-44-9
2. Blauw GJ, Lagaay AM, Smelt AHM, Westebdorp RGJ (1997) Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28:946-50
3. Delanty N, Vaughan CJ (1997) Vascular effects of statins in stroke. Stroke 28:2315-20
4. Derdeyn CP, Videen TO, Yundt KD, Fritsch SM, Carpenter DA, Grubb RL, Powers WJ (2002) Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. Brain 125:595-607
5. Derdeyn CP, Yundt KD, Videen TO, Carpenter DA, Grubb Jr RL, Powers WJ (1998) Increased oxygen extraction fraction is associated with prior ischemic events in patients with carotid occlusion. Stroke 29:754-8
6. Endres M, Laufs U, Huang Z, Nakamure T, Huang P, Moskowitz MA, Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutary (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880-5
7. Fox PT, Perlmutter JS, Raichle ME (1985) A stereotactic method of anatomical localization for positron emission tomography. J Comput Assist Tomogr 9:141-53
8. Grubb Jr RL, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Spitznagel EL, Powers WJ (1998) Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 280:1055-60
9. Heart Protection Study Collaborative G (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet 360:7-22
10. 2O. I. Theory and error analysis. J Nucl Med 24:782-9
11. Huang A, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA (1996) Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow and Metab 16:981-7
12. Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA (1994) Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow and Metab 14:175-92
13. Laufs U, La Fata V, Plutsky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-35
14. Martin WRW, Powers WJ, ME R (1987) Cerebral blood volume measured with inhaled C15O and positron emission tomography. I Cereb Blood Flow and Metab 7:421-6
15. Mintun MA, Raichle ME, Martin WRW, Herscovitch P (1984) Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nuc Med 25:177-87
16. Morikawa E, Huang Z, Moskowitz MA (1992) -Arginine decreases infarct size caused by middle cerebral arterial occlusion in SHR. Am J Physiol 263:H1632-5
17. Naritomi HMJ, Sakai F, Yamaguchi F, Shaw T (1979) Effects of advancing age on regional cerebral blood flow. Studies in normal subjects and subjects with risk factors for atherothrombotic stroke. Arch Neurol 36:410-6
18. Powers WJ, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Grubb Jr RL (2000) Benign prognosis of never-symptomatic carotid occlusion. Neurology 54:878-82
19. Powers WJ, Raichle ME (1985) Positron emission tomography and its application to the study of cerebrovascular disease in man. Stroke 16:361-76
20. Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J (1983) Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med 24:790-8
21. Rodriguez G, Warkentin S, Risberg J, Rosadini G (1988) Sex differences in regional cerebral blood flow. J Cereb Blood Flow Metab 8:783-9
22. Rosenson RS, Tangney CC (1998) Antiatherothrombotic properties of statins. JAMA 279:1643-50
23. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-9
24. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease. The Scandinavian Simvastatin Suvival Study (4S). Lancet 344:1383-9
25. Scandinavian Simvastatin Suvival Study Group (1995) Baseline cholesterol and treatment effect in the Scandinavian Simvastatin Suvival Study (4S). Lancet 345:1274-5
26. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-58
27. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 335:1301-7
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288:2998-3007
29. Videen TO, Perlmutter JS, Herscovitch P, Raichle ME (1987) Brain blood volume, flow, and oxygen utilization measured with 15O radiotracers and positron emission tomography: revised metabolic computations. J Cereb Blood Flow Metab 7:513-6
30. Zhang F, Iadecola C (1994) Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors. J Cereb Blood Flow and Metab 14:574-80